Entrectinib is in clinical development for the oral treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with ROS1 genetic rearrangement. NSCLC makes up the majority of lung cancer cases and can be classified according to how far the cancer has spread. Stage III, or locally advanced NSCLC is when the cancer has spread within the lungs and surrounding areas. Stage IV NSCLC is when the cancer has spread to other locations and organs within the body. Many different factors can increase the risk of developing NSCLC, including certain genetic changes, such as changes to the ROS1 gene which lead to increased levels of the ROS1 protein. Increased levels of ROS1 have been found in many different types of cancer, including NSCLC, and are thought to contribute to the development of cancer.
Entrectinib is a drug that specifically targets and blocks the ROS1 protein overproduced in many types of cancers including NSCLC. Preclinical trials suggest it may be more potent in targeting ROS1 than the currently approved therapy crizotinib. If licenced entrectinib would provide an additional specific treatment option for patients with ROS rearranged, locally advanced or metastatic NSCLC.
Daratumumab injected under the skin (subcutaneous formulation) is in development for the treatment multiple myeloma (MM) as an alternative to currently approved daratumumab intravenous formulation. MM is a rare, incurable cancer of the plasma cells in the bone marrow where large amounts of abnormal plasma cells are produced and interfere with the production of platelets, red and white blood cells. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (‘relapsed’ MM). Eventually the periods without symptoms will shorten and the illness will become immune to the drugs given to treat it (‘refractory’ MM).